A variety of immune checkpoint (PD-1, PD-L1, and CTLA-4) inhibitors (ICIs) are being used in the treatment of advanced BLCA, and clinical studies have shown that they are reliable in terms of safety and efficacy. This evidence concerns the gene CD274 and bladder transitional cell carcinoma.